Zhang Nan, Nao Jianfei, Dong Xiaoyu
Department of Neurology, China Medical University Seventh Clinical College, Fushun, Liaoning P.R. China.
Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P.R. China.
Curr Neuropharmacol. 2025;23(6):728-754. doi: 10.2174/1570159X23666241211095018.
Alzheimer's Disease (AD) is the most common dementia in clinics. Despite decades of progress in the study of the pathogenesis of AD, clinical treatment strategies for AD remain lacking. Apigenin, a natural flavonoid compound, is present in a variety of food and Chinese herbs and has been proposed to have a wide range of therapeutic effects on dementia.
To clarify the relevant pharmacological mechanism and therapeutic effect of apigenin on animal models of AD.
Computer-based searches of the PubMed, Cochrane Library, Embase, and Web of Science databases were used to identify preclinical literature on the use of apigenin for treating AD. All databases were searched from their respective inception dates until June 2023. The meta-analysis was performed with Review manager 5.4.1 and STATA 17.0.
Thirteen studies were eventually enrolled, which included 736 animals in total. Meta-analysis showed that apigenin had a positive effect on AD. Compared to controls, apigenin treatment reduced escape latency, increased the percentage of time spent in the target quadrant and the number of plateaus traversed; apigenin was effective in reducing nuclear factor kappa-B (NF-κB) p65 levels; apigenin effectively increased antioxidant molecules SOD and GSH-px and decreased oxidative index MDA; for ERK/CREB/BDNF pathway, apigenin effectively increased BDNF and pCREB molecules; additionally, apigenin effectively decreased caspase3 levels and the number of apoptotic cells in the hippocampus.
The results show some efficacy of apigenin in the treatment of AD models. However, further clinical studies are needed to confirm the clinical efficacy of apigenin.
阿尔茨海默病（AD）是临床上最常见的痴呆症。尽管在AD发病机制的研究方面取得了数十年的进展，但AD的临床治疗策略仍然匮乏。芹菜素是一种天然黄酮类化合物，存在于多种食物和中草药中，有人提出它对痴呆症具有广泛的治疗作用。
阐明芹菜素对AD动物模型的相关药理机制和治疗效果。
通过基于计算机检索PubMed、Cochrane图书馆、Embase和Web of Science数据库，以识别使用芹菜素治疗AD的临床前文献。所有数据库均从各自的起始日期检索至2023年6月。使用Review manager 5.4.1和STATA 17.0进行荟萃分析。
最终纳入13项研究，共736只动物。荟萃分析表明，芹菜素对AD有积极作用。与对照组相比，芹菜素治疗可缩短逃避潜伏期，增加在目标象限停留的时间百分比和穿越平台的次数；芹菜素可有效降低核因子κB（NF-κB）p65水平；芹菜素可有效增加抗氧化分子超氧化物歧化酶（SOD）和谷胱甘肽过氧化物酶（GSH-px），并降低氧化指标丙二醛（MDA）；对于细胞外信号调节激酶/环磷腺苷反应元件结合蛋白/脑源性神经营养因子（ERK/CREB/BDNF）通路，芹菜素可有效增加脑源性神经营养因子（BDNF）和磷酸化环磷腺苷反应元件结合蛋白（pCREB）分子；此外，芹菜素可有效降低半胱天冬酶3（caspase3）水平和海马体中的凋亡细胞数量。
结果显示芹菜素在治疗AD模型方面有一定疗效。然而，需要进一步的临床研究来证实芹菜素的临床疗效。
